Literature DB >> 33958278

Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation.

Emrah Gecili1, Weiji Su2, Cole Brokamp3, Eleni-Rosalina Andrinopoulou4, Francis J LaRosa Iii5, Teresa Pestian1, John P Clancy6, George M Solomon7, John J Brewington8, Rhonda D Szczesniak9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33958278      PMCID： PMC8803536          DOI： 10.1016/j.jcf.2021.04.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.527


× No keyword cloud information.
  7 in total

1.  Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.

Authors:  Sonya L Heltshe; Steven M Rowe; Michelle Skalland; Arthur Baines; Manu Jain
Journal:  Am J Respir Crit Care Med       Date:  2018-06-01       Impact factor: 21.405

2.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

3.  Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.

Authors:  Rhonda D Szczesniak; Dan Li; Weiji Su; Cole Brokamp; John Pestian; Michael Seid; John P Clancy
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

4.  VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Authors:  Jane C Davies; Samuel M Moskowitz; Cynthia Brown; Alexander Horsley; Marcus A Mall; Edward F McKone; Barry J Plant; Dario Prais; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; Ahmet Uluer; Charlotte M McKee; Sarah Robertson; Rebecca A Shilling; Christopher Simard; Fredrick Van Goor; David Waltz; Fengjuan Xuan; Tim Young; Steven M Rowe
Journal:  N Engl J Med       Date:  2018-10-18       Impact factor: 91.245

5.  VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Authors:  Dominic Keating; Gautham Marigowda; Lucy Burr; Cori Daines; Marcus A Mall; Edward F McKone; Bonnie W Ramsey; Steven M Rowe; Laura A Sass; Elizabeth Tullis; Charlotte M McKee; Samuel M Moskowitz; Sarah Robertson; Jessica Savage; Christopher Simard; Fredrick Van Goor; David Waltz; Fengjuan Xuan; Tim Young; Jennifer L Taylor-Cousar
Journal:  N Engl J Med       Date:  2018-10-18       Impact factor: 91.245

6.  Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies.

Authors:  John J Brewington; Erin T Filbrandt; F J LaRosa; Jessica D Moncivaiz; Alicia J Ostmann; Lauren M Strecker; John P Clancy
Journal:  JCI Insight       Date:  2018-07-12

7.  Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators.

Authors:  Iwona M Pranke; Aurélie Hatton; Juliette Simonin; Jean Philippe Jais; Françoise Le Pimpec-Barthes; Ania Carsin; Pierre Bonnette; Michael Fayon; Nathalie Stremler-Le Bel; Dominique Grenet; Matthieu Thumerel; Julie Mazenq; Valerie Urbach; Myriam Mesbahi; Emanuelle Girodon-Boulandet; Alexandre Hinzpeter; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.